Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 2/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | REN | P00797 | 1/20 | 0.39 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.38 |
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13499626 | 0.95 | KMT2A (0.50) | KMT2AALDH1A1CTSKCTSLCTSB | |
| SCHEMBL13499651 | 0.95 | KMT2A (0.47) | KMT2AALDH1A1CTSKCTSLCTSB | |
| SCHEMBL13499668 | 0.90 | LTA4H (0.43) | KMT2AALDH1A1CTSKCTSLCTSB | |
| SCHEMBL13499659 | 0.85 | LTA4H (0.49) | KMT2AALDH1A1CTSKCTSLCTSB | |
| SCHEMBL13499644 | 0.85 | LTA4H (0.46) | KMT2AALDH1A1CTSKCTSLCTSB | |
| SCHEMBL13499653 | 0.83 | LTA4H (0.43) | KMT2AALDH1A1CTSKLTA4HTP53 | |
| SCHEMBL13500209 | 0.83 | CA2 (0.44) | KMT2AALDH1A1CTSKCTSLCTSB | |
| SCHEMBL13461380 | 0.82 | CA2 (0.43) | KMT2AALDH1A1CTSKCTSLCTSB | |
| SCHEMBL13499628 | 0.81 | CA2 (0.40) | KMT2ACTSKCTSLCTSBCA2 | |
| SCHEMBL13499664 | 0.81 | LTA4H (0.45) | KMT2AALDH1A1CTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048541-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-02-25 | — | — | US | disclosed |
| US-7655647-B2 | Substituted lactams as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048541-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BACE1, APP, APH1A | KMT2A 4379/4885ALDH1A1 3896/4885CTSK 933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.